Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: The use of fulvestrant, a parenteral endocrine agent, in intestinal obstruction due to metastatic lobular breast carcinoma | BioMed Central World Journal of Surgical Oncology Open Access Case report The use of fulvestrant a parenteral endocrine agent in intestinal obstruction due to metastatic lobular breast carcinoma Jasmine YM Tang Rajendra Singh Rampaul and Kwok L Cheung Address Division of Breast Surgery University of Nottingham Nottingham UK Email Jasmine YM Tang - jaytea@ Rajendra Singh Rampaul - Kwok L Cheung - Corresponding author Published I December 2008 Received 3 July 2008 World Journal of Surgical Oncology 2008 6 128 doi 1477-7819-6-128 Accepted 1 December 2008 This article is available from http content 6 I I28 2008 Tang et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background The role of fulvestrant in the management of intestinal obstruction associated with lobular carcinoma has not been specifically described. Case presentation Herein we present two cases where fulvestrant as the only available parenteral endocrine agent for postmenopausal advanced breast cancer has the opportunity to provide a means to initiate treatment in those patients who present with varying degrees of intestinal obstruction. Conclusion Fulvestrant may obviate the use of chemotherapy while achieving sustained clinical benefit with less toxicity in appropriately selected patients. Background Fulvestrant Faslodex is a relatively new oestrogen receptor ER antagonist with a novel mode of action it binds blocks and increases degradation of ER 1 . Fulvestrant is licensed for treatment of postmenopausal women with hormone receptor-positive advanced breast cancer HR ABC progressing or recurring on anti-oes-trogen therapy. However it is also active in the first-line .
